BUFFALO, N.Y., Oct. 19, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today that H. Shep Wild, President and Chief Executive Officer, will present a company overview at the Biotechnology Industry Organization's 10th Annual BIO Investor Forum in San Francisco, CA on Wednesday, October 26 at 9:00 am.
The BIO Investor Forum features presentations by leading private and emerging public biotechnology companies to healthcare venture and private equity investors, buy-side and sell-side investment companies and biopharmaceutical and industry business development and licensing executives.
CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumors in that its unique mechanism of action disrupts the signaling of FAK in tumors by targeting specific protein to protein bindings. CureFAKtor scientists first discovered FAK in human tumors approximately 20 years ago. FAK is much like a force field that cocoons cancer cells and allows them to survive the effects of chemotherapy, radiation and other natural processes designed to execute aberrant cancer cells. Since FAK is over-expressed in virtually all solid tumors, the technology has broad applicability in oncology.
More than 40 compounds have been identified that target FAK signaling sites. In preclinical studies, lead small molecule oral compound CFAK-C4 demonstrated efficacy in a number of cancers including pancreatic, breast, advanced melanoma and neuroblastoma. The Company's second product candidate, CFAK-Y15 is being investigated for the treatment of breast, pancreatic, neuroblastoma and colon cancer. The Company has promising results with CFAK-Y15 in lung cancer and glioblastoma.
CureFAKtor received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options, and is planning a Phase I clinical study in 2012.
Additional information about the company may be found at www.curefaktor.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for CureFAKtor Pharmaceuticals that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.
Rx Communications Group, LLC
Vice President, Public Relations
SOURCE CureFAKtor Pharmaceuticals, LLC